Abbott Presents New Approach for Treating Attention-Deficit Hyperactivity Disorder
Watch a short video explaining how NNRs work.
Attention-Deficit Hyperactivity Disorder (ADHD), an ailment historically
associated with childhood, persists into adulthood in more than two-thirds of
cases. While medical treatment can improve the symptoms of ADHD, currently
approved treatments often cause undesirable side effects, including increases
in heart rate and blood pressure.
Abbott and other leading scientists will present new Phase II data showing that ABT-089, a selective
neuronal nicotinic receptor (NNR) agonist, is a potentially effective and safe
treatment for adults with Attention-Deficit Hyperactivity Disorder (ADHD). The
studies are being presented at the American Psychiatric Association 161st
Annual Meeting in Washington, D.C. Phase II study
results show that ABT-089 appears to significantly improve the core symptoms of
ADHD, improve quality-of-life and work effectiveness, and reduce overall work
impairment in adults with ADHD.
Data also revealed that ABT-089 appears to be generally well tolerated with
no significant negative effects on sleep, appetite or vital signs (heart rate
and blood pressure). NNRs modulate the release of several important
neurotransmitters, such as acetylcholine and dopamine, and are an important
class of ion channels (molecular "gates" that control the flow of ions
in and out of cells and regulate neuron signaling) that have been associated
with a number of neurological conditions. Abbott scientists have been among the
leaders in advancing the understanding of the therapeutic potential of NNRs for
more than a decade and have published more than 75 research studies in this
area.
Additional information:
More Features